AI tools for fundraising, business development and finance are now widely available, but while large pharma companies are starting to deploy them at scale, most smaller biotechs have yet to embed them into their core business processes due to constraints around budget, risk and governance. The panel will examine how this gap is reshaping deal‑making dynamics, what it means for both sides of the table, and how smaller companies can respond in a legally robust and practically actionable way, including a pointer to a forthcoming webinar series that will continue the discussion with deeper, hands‑on insights.
Tuesday, May 5, 14:00 - 14:45, room Delhi
| Name | Position | Institution |
|---|---|---|
| Philipp Gutzwiller | Managing Partner | CFS Advisors LLP |
| Name | Position | Institution |
|---|---|---|
| Luca Dal Molin | Partner | Homburger |
| Urs Breitenstein | Partner | Hoffmann & Partner |
| Avaleigh Milne | Global Head of Business Development Strategy & Practice, Pharma Partnering | Roche |
| Damian Kemper | Developer | Werchota.ai |
| Matti Kesti | CSO | Floatz.ai |
Homburger is one of the largest Swiss law firms, with more than 160 professionals, advising companies and entrepreneurs on complex business law matters in Switzerland and internationally. The firm supports clients in transactions, regulatory matters and disputes, combining specialized legal expertise with an integrated team approach and a strong global network. Homburger's Healthcare / Life Science team integrates M&A, financing, venture capital, capital markets, IP/IT, commercial agreements, regulatory, competition, and tax expertise to help clients navigate complexity, manage risk and achieve their commercial objectives.
